TING-AN YENCHING-CHIA WANG2020-12-172020-12-1720171875-9572https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011589915&doi=10.1016%2fj.pedneo.2016.12.003&partnerID=40&md5=ce1cd8feaa790840b14e3d4265653fddhttps://scholars.lib.ntu.edu.tw/handle/123456789/527181[SDGs]SDG3ibuprofen; indometacin; prostaglandin synthase; ibuprofen; nonsteroid antiinflammatory agent; prostaglandin synthase inhibitor; artery ligation; birth weight; clinical effectiveness; clinical practice; disease course; drug efficacy; drug safety; drug treatment failure; Editorial; gestational age; human; infant; managed care; mortality risk; necrotizing enterocolitis; patent ductus arteriosus; population; prematurity; repeated drug dose; retrospective study; risk assessment; risk factor; unspecified side effect; urine volume; newborn; newborn disease; patent ductus arteriosus; prematurity; treatment outcome; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Treatment Outcomeeditorial10.1016/j.pedneo.2016.12.003281857782-s2.0-85011589915